Ignite Creation Date:
2024-05-06 @ 9:14 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02937103
Status:
UNKNOWN
Last Update Posted:
2019-06-25
First Post:
2016-10-14
Brief Title:
A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
Sponsor:
Southwest Hospital China
Organization:
Southwest Hospital China
Study Overview
Official Title:
A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
Status:
UNKNOWN
Status Verified Date:
2019-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The overall purpose of this study is to explore the therapeutic effect of CD123-targeted chimeric antigen receptor TCAR-T cells in the treatment of Myeloid Malignancies
Detailed Description:
Great progress has been made in the treatment of relapsed and refractory B cell malignancies with CD19-targeted CAR-T cells However for myeloid malignancies which has higher morbidity trials of CAR-T is few CD123 is expressed on most myeloid leukemia cells so it is a ideal target for CAR-T Some researches have revealed that CD123 is a marker of leukemia stem cells which indicates that the eradication of CD123 cells may prevent relapse of leukemia This trial is designed and conducted to test the safety and effectiveness of CD123-targeted CAR-T
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None